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genital heart disease, 4 connective tissue disease; 9 functional class III and 2 class II at
baseline) were treated with sitaxsentan for one year. Mean pulmonary arterial pressure
(mPAP), cardiac output (CO), and pulmonary vascular resistance (PVR) were measured
at baseline prior to starting sitaxsentan, and again after one year of treatment. All follow-
up measurements were performed at least 24 hours after the last sitaxsentan dose, i.e.
nadir of effect.
Results: All 11 patients improved clinically during the first 7 months of therapy. One
patient deteriorated at 7 months. The other 10 patients continued to improve (to class II),
or stayed at class II, at one year. Data shown below are mean ± SD for the 10 patients; p
values are for two-tailed paired t-tests.
Conclusion: Long-term treatment with the selective ETA receptor antagonist sitaxsentan
improves functional class and hemodynamics in patients with PAH, and interrupts the
usual downhill course of the disease.
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Background: Epoprostenol (EPO) and Bosentan (BO) therapy alter the natural history of
patients (pts) with pulmonary arterial hypertension (PAH) due to either primary (PPH) or
secondary from scleroderma spectrum of diseases (SPH). Though, a number of clinical
and hemodynamic variables have been previously shown to predict survival in untreated
PAH pts, the predictors of outcome in EPO or BO treated pts are unknown.
Method: Baseline clinical (age, diagnosis, NYHA class), hemodynamic (right atrial, pul-
monary artery, pulmonary wedge, systemic arterial pressures, cardiac output, mixed
venous oxygen saturation), and laboratory (serum sodium, creatinine, bilirubin, hemoglo-
bin) variables were collected in PAH patients (n=180; 137 females, 43 males; 94 PPH, 86
SPH; 124 NYHA Class III and 56 Class IV) treated with either EPO (n=115) or BO (n=65)
for a mean of 492 days (range 2-1509). Endpoints recorded included death or combined
death and all cause hospitalization.
Results: Cumulative 1 year freedom from death for the entire population was 88% and
freedom from death and hospitalization 57%. Univariate analysis showed that NYHA
class, cardiac output, mixed venous oxygen saturation (MVOS), right atrial pressure,
serum sodium, creatinine and hemoglobin predicted outcome. Multivariate analysis
revealed that MVOS was the strongest predictor followed by NYHA Class.
Conclusion: Baseline MVOS and NYHA class are the strongest predictors of outcome in
PAH pts treated with either EPO or BO therapy. 
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Background:
It is unknown if the amount of brain natriuretic peptide (BNP) secreted by the right ventri-
cle (RV) is accurately reflected in the peripheral circulation in patients with pulmonary
hypertension.We hypothesized that BNP levels in the pulmonary artery would be higher
than those drawn from the peripheral circulation.
Methods:
Simultaneous samples for BNP measurement were drawn from the pulmonary artery,
femoral artery and femoral vein in 20 patients undergoing cardiac catheterization for the
evaluation of pulmonary hypertension. Patients had no CAD and all had normal pulmo-
nary capillary wedge pressures. Differences between BNP values from each location
were assessed with the Wilcoxon signed rank sum test.
Results:
The mean (SD) pulmonary arterial systolic pressure was 67.8 (+/- 22.7) mmHg. The
median BNP values (pg/ml) drawn from the pulmonary artery, femoral artery and femoral
vein were 236, 200, and 190.5, respectively. Individual values from the various sites are
shown graphically below. BNP levels in the femoral vein were significantly lower than in
the pulmonary artery (p=0.0002). There were also significant differences between BNP
levels in the femoral vein and femoral artery (p=0.011).
Conclusions:
Among patients with pulmonary hypertension, BNP levels in the pulmonary artery are
significantly higher than in the femoral vein. This regional variation should be taken into
consideration when BNP levels are to be used in the evaluation of patients with pulmo-
nary HTN.. 
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To determine if serial International Normalized Ratios (INRs) provide adequate warning
in predicting the onset of warfarin-related bleeding. The cohort consisted of 2,391
patients managed in our Anticoagulation Service at Brigham and Women’s Hospital from
April 1999-July 2003. We performed a nested case-control study, selecting two controls
per case matched for age, gender, indication for warfarin, and duration of management
by our Anticoagulation Service. The incidence of bleeding was 1.3%: major bleeding in
0.63% (n=15) and minor in 0.71% (n=17). Baseline characteristics and warfarin doses
were similar in the groups. The event INRs (5.9±5.9 vs 2.3±0.7) and penultimate INRs
(3.0±1.2 vs 2.1±0.8) were higher in cases than controls, respectively (p<0.001). The pen-
ultimate INR was obtained 11.6±17.8 days prior to the event in cases and 18.3±28.0
days prior to the matched date in controls (p=0.22). Although obtained earlier (18.4±20.5
vs 31.0±31.3; p=0.048), the antepenultimate INR was similar in both groups (2.8±2.1 vs
2.3±0.8; p=0.11). When pooled antepenultimate, penultimate, and event INRs were plot-
ted in relation to the time before the onset of bleeding (Figure), abnormally high INRs
were observed shortly before the bleeding began. We conclude that serial INRs are poor
predictors of hemorrhagic events. Antepenultimate INRs are similar in cases and con-
trols. There appears to be only a brief warning period during which a slightly elevated
penultimate INR predicts an imminent bleeding event. 
Baseline Year 1 p Value
mPAP (mm Hg) 43.9 ± 13.5 45 ± 15.2 N.S.
CO (L/min) 4.3 ± 0.9 5.4 ± 1.1 0.002
PVR (dynes-cm-sec-5) 742 ± 341 585 ± 246 0.04
